Targeting the EIT-mediated immunosuppressive environment involving B-7-H3, B7-H4, TIM3, and LAG3, in addition to PD-1/PD-L1 and CTLA-4, may be beneficial in designing novel therapeutic strategies for PCa [18] (Figure 5). The gene discussed is CTLA4; the disease is posterior cortical atrophy.